Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
University of California, San Francisco · Predicted Tauopathies, Including · Progressive Supranuclear Palsy
Phase 1
Completed
12
2019-04
Evidence dashboardStudies since 2006Updated Jul 31, 2026
DavunetideClinical Trials.
A source-linked view of every Davunetide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 5
- Recruiting
- 0
- Completed
- 5
- Terminated
- 0
- Results posted
- 1
- Average enrollment
- 153
- Countries
- 6
- Highest phase
- Phase 3
Largest indexed study
313 participants · NCT01110720 →Developer / research origin
Allon Therapeutics
Evidence summary
Activity is not efficacy.
Davunetide appears in 5 indexed studies: 0 recruiting, 5 completed and 1 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Davunetide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
No studies in this snapshot.
NCT IDStudyPhase / statusEnrollmentUpdated
A Multicenter Study of NAP (AL-108) in Schizophrenia
University of California, Los Angeles · Schizophrenia
Phase 2
Completed
63
2017-03
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Allon Therapeutics · Progressive Supranuclear Palsy
Phase 2 / Phase 3
Completed
313
2013-01
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
Allon Therapeutics · Mild Cognitive Impairment
Phase 2
Completed
234
2012-10
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
Allon Therapeutics · Mild Cognitive Impairment, So Stated
Phase 2
Completed
144
2012-10
No studies in this snapshot.
Full study index
Search Davunetide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
5 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 17589313 ↗Antoniades CA, Altham PM, Mason SL, Barker RA, Carpenter R. Saccadometry: a new tool for evaluating presymptomatic Huntington patients. Neuroreport. 2007 Jul 16;18(11):1133-6. doi: 10.1097/WNR.0b013e32821c560d.Linked from NCT01056965PMID 20477368 ↗Antoniades CA, Bak TH, Carpenter RH, Hodges JR, Barker RA. Diagnostic potential of saccadometry in progressive supranuclear palsy. Biomark Med. 2007 Dec;1(4):487-90. doi: 10.2217/17520363.1.4.487.Linked from NCT01056965PMID 10037502 ↗Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999 Mar;72(3):1283-93. doi: 10.1046/j.1471-4159.1999.0721283.x.Linked from NCT01056965PMID 19029129 ↗Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 Jan;132(Pt 1):156-71. doi: 10.1093/brain/awn291. Epub 2008 Nov 23.Linked from NCT01056965PMID 12833363 ↗Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54 Suppl 5:S15-9. doi: 10.1002/ana.10570. No abstract available.Linked from NCT01056965PMID 8636410 ↗Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996 May 15;97(10):2299-307. doi: 10.1172/JCI118672.Linked from NCT01056965PMID 17579875 ↗Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL 3rd, Schneider JA, Grinberg LT, Halliday G, Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG, Trojanowski JQ, Mann DM; Consortium for Frontotemporal Lobar Degeneration. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007 Jul;114(1):5-22. doi: 10.1007/s00401-007-0237-2. Epub 2007 Jun 20.Linked from NCT01056965PMID 9153155 ↗Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997 May;48(5 Suppl 6):S10-6. doi: 10.1212/wnl.48.5_suppl_6.10s.Linked from NCT01056965
Related pages
Keep researching Davunetide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.